anxiety circuitry

Every compound in the sci-wiki that affects anxiety circuitry; the ones you can source are floated to the front, then the reference-only entries. Tap any for the full entry, mechanism, and outlets.

0 sourced · 3 reference

←anxiety circuitry3/3

Neuropeptide

Nelivaptan

Nelivaptan chased a genuinely novel idea in psychiatry, blocking the vasopressin V1b receptor instead of tuning serotonin or GABA, on the logic that vasopressin drives the body's stress and HPA-axis response and that dialing it down might relieve anxiety and depression without the sedation or dependence baggage of benzodiazepines. Sanofi-Aventis ran it through four large, well-controlled Phase II trials for major depressive disorder and generalized anxiety disorder between 2006 and 2008, comparing it against escitalopram and paroxetine. The results were unambiguous in the wrong direction; nelivaptan showed no meaningful benefit over placebo in GAD and only inconsistent signals in depression, closing the book on vasopressin antagonism as an anxiety treatment for over a decade.

reference

Serotonergic

Robalzotan

Robalzotan was AstraZeneca's attempt to flip the SSRI script; instead of blocking reuptake, it selectively antagonized presynaptic 5-HT1A autoreceptors, a mechanism meant to speed up and amplify serotonin release compared to a standard SSRI. The theory was sound enough to carry it into a 385-patient, paroxetine-controlled Phase II depression trial, plus separate programs for irritable bowel syndrome and overactive bladder. None of it panned out; the depression trial showed no separation from placebo, and the GI and urology programs were quietly closed out by 2005. It is a clean case study in how a mechanistically elegant idea can still fail the only test that matters, a randomized trial.

reference

Sigma-1 Agonist

Siramesine

Siramesine came out of H. Lundbeck's sigma-receptor chemistry program in Denmark in the mid-1990s, and it is still one of the most selective sigma-2 ligands ever made, with subnanomolar affinity and roughly 140-fold preference for sigma-2 over sigma-1. It moved into human testing for anxiety and depression on the strength of strong anxiolytic- and antidepressant-like signals in rodent models. Lundbeck quietly shelved the psychiatric program in the mid-2000s without publishing a clear efficacy failure; the company's own statements pointed to commercial rather than safety reasons. The molecule did not disappear, though; oncology researchers picked it back up because at higher concentrations it destabilizes lysosomal membranes and kills tumor cells, giving siramesine a stranger second career than most abandoned psychiatric drugs get.

reference